https://cartchina.com/ https://cartchina.com/car-t-or-a-bispecific-antibody-for-r-r-dlbcl-new-csco-2026-analyses-offer-more-clues/ 2026-10-11T22:28:52+08:00 https://cartchina.com/fucaso-eque-cel-worlds-first-fully-human-bcma-targeted-car-t-therapy-approved-in-china-for-refractory-and-relapsed-multiple-myeloma/ 2026-10-11T21:07:02+08:00 https://cartchina.com/2025-ash-professor-yan-xu-real-world-data-support-the-combination-of-eque-cel-and-asct-in-ultra-high-risk-multiple-myeloma/ 2026-10-07T20:59:51+08:00 https://cartchina.com/ims-2026-faster-dissociation-lower-exhaustion-new-fumanba-1-analysis-links-eque-cel-persistence-to-longer-mrd-negative-control/ 2026-10-07T20:48:14+08:00 https://cartchina.com/china-enters-car-t-cell-therapy-era/ 2026-10-07T17:01:29+08:00 https://cartchina.com/ims-2026-real-world-data-from-281-rrmm-patients-further-support-eque-cel-fucaso/ 2026-10-06T12:49:47+08:00 https://cartchina.com/carteyva-shows-survival-benefit-in-relapsed-or-refractory-follicular-lymphoma/ 2026-10-05T00:54:42+08:00 https://cartchina.com/carteyva-approved-for-marketing-in-macao-marking-a-new-step-in-the-global-expansion-of-chinese-car-t-therapy/ 2026-10-05T00:44:21+08:00 https://cartchina.com/relma-cel-carteyva-approved-for-relapsed-or-refractory-mantle-cell-lymphoma/ 2026-10-05T00:23:13+08:00 https://cartchina.com/relma-cel-approved-in-china-a-new-chapter-for-car-t-cell-therapy/ 2026-10-04T23:50:44+08:00 https://cartchina.com/yorwida-inati-cel-approved-in-china-for-relapsed-refractory-large-b-cell-lymphoma/ 2026-10-03T22:57:34+08:00 https://cartchina.com/chinas-first-approved-car-t-cell-therapy-the-story-of-axicabtagene-ciloleucel/ 2026-10-03T22:50:33+08:00 https://cartchina.com/2026-csco-new-comparative-data-adds-to-clinical-evidence-for-relma-cel-car-t-cell-therapy-in-r-r-dlbcl/ 2026-10-02T19:17:26+08:00